WOXITIL 1.5 contains Cefuroxime 1.5 g Injection, positioned for selected bacterial infections requiring injectable cephalosporin therapy. Its parenteral presentation offers convenient systemic administration in hospital, surgical and physician-supervised settings, making it relevant to moderate and severe susceptible infections. A strong addition to the PCD Pharma Injectable Antibiotic portfolio, providing a clinically established second-generation cephalosporin option for institutional and prescription-driven markets.
Selected susceptible bacterial infections requiring parenteral therapy.
No.
It provides systemic antibiotic exposure when oral therapy is unsuitable or when the clinical severity warrants parenteral treatment.
Use only under medical supervision after reviewing allergy history and infection severity. Follow appropriate dosing and duration recommendations, and use microbiological guidance where available. Consider renal function in dose planning for appropriate patients. Monitor clinical response, hypersensitivity and antibiotic-associated diarrhea throughout treatment.
Common side effects may include diarrhea, nausea, vomiting, abdominal discomfort, headache, rash and injection-site reactions. Hypersensitivity reactions are possible in patients allergic to cephalosporins or related beta-lactam antibiotics. Antibiotic-associated diarrhea can occasionally become significant. Persistent diarrhea, severe rash, facial swelling, difficulty breathing or other unexpected reactions require prompt medical evaluation and appropriate treatment.
WOXITIL 1.5: Cefuroxime is a second-generation cephalosporin that inhibits bacterial cell-wall synthesis by binding to penicillin-binding proteins and interfering with peptidoglycan formation. This weakens the structural integrity of susceptible bacteria and results in bactericidal activity. The injectable formulation provides systemic antibacterial exposure and is particularly useful in selected moderate to severe infections where parenteral cephalosporin therapy is appropriate.
